share_log

SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Gene Salkind(53.1%)

SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Gene Salkind(53.1%)

SC 13D/A：超过5%持股股东披露文件(修正)-Gene Salkind(53.1%)
美股SEC公告 ·  08/23 04:05

Moomoo AI 已提取核心信息

On August 6, 2024, Dr. Gene Salkind, a practicing neurosurgeon and Chairman of the Board of Mobiquity Technologies, Inc., filed an amendment to the Schedule 13D, disclosing a significant ownership stake in the company. The filing, which is an update to a previous Schedule 13D filing, indicates that Dr. Salkind, along with his wife and a family trust, beneficially owns 8,805,239 common shares of Mobiquity Technologies, representing approximately 53.1% of the company's outstanding common shares. This ownership includes convertible notes, options, and warrants for additional shares. The filing also notes that Dr. Salkind has no current plans that would result in any major changes to the company's structure or operations as outlined in the Schedule 13D instructions. The acquisition of shares by Dr. Salkind and his associated parties was funded through personal funds over several years. Notably, the reporting person received 7,675,160 common shares upon the automatic conversion of Series H Preferred Stock after the company's stock traded above $2 per share between July 24, 2024, and August 6, 2024. This conversion also included additional shares for accrued and unpaid dividends.
On August 6, 2024, Dr. Gene Salkind, a practicing neurosurgeon and Chairman of the Board of Mobiquity Technologies, Inc., filed an amendment to the Schedule 13D, disclosing a significant ownership stake in the company. The filing, which is an update to a previous Schedule 13D filing, indicates that Dr. Salkind, along with his wife and a family trust, beneficially owns 8,805,239 common shares of Mobiquity Technologies, representing approximately 53.1% of the company's outstanding common shares. This ownership includes convertible notes, options, and warrants for additional shares. The filing also notes that Dr. Salkind has no current plans that would result in any major changes to the company's structure or operations as outlined in the Schedule 13D instructions. The acquisition of shares by Dr. Salkind and his associated parties was funded through personal funds over several years. Notably, the reporting person received 7,675,160 common shares upon the automatic conversion of Series H Preferred Stock after the company's stock traded above $2 per share between July 24, 2024, and August 6, 2024. This conversion also included additional shares for accrued and unpaid dividends.
2024年8月6日，Mobiquity Technologies, Inc.董事长及实践神经外科医生Gene Salkind博士提交了13D表格的修正，披露了对该公司的重大持股。这份文件是对先前13D表格的更新，显示Gene Salkind博士及其妻子和家族信托受益持有Mobiquity Technologies约53.1%的流通股，共计880,523,900股。这些持股包括可转债、期权和股票认购权证。文件还指出，Gene Salkind博士目前没有任何会导致公司结构或运营发生重大变化的计划，这一点也在13D表格的说明中有所体现。Gene Salkind博士及其相关方持有的股份是通过个人资金在多年的时间里获得的。值得注意的是，报告人在2024年7月24日至2024年8月6日期间，公司股票交易价格超过每股2美元后，自动将H系列优先股转换为7,675,160普通股，此转换包括应计未支付股息的附加股份。
2024年8月6日，Mobiquity Technologies, Inc.董事长及实践神经外科医生Gene Salkind博士提交了13D表格的修正，披露了对该公司的重大持股。这份文件是对先前13D表格的更新，显示Gene Salkind博士及其妻子和家族信托受益持有Mobiquity Technologies约53.1%的流通股，共计880,523,900股。这些持股包括可转债、期权和股票认购权证。文件还指出，Gene Salkind博士目前没有任何会导致公司结构或运营发生重大变化的计划，这一点也在13D表格的说明中有所体现。Gene Salkind博士及其相关方持有的股份是通过个人资金在多年的时间里获得的。值得注意的是，报告人在2024年7月24日至2024年8月6日期间，公司股票交易价格超过每股2美元后，自动将H系列优先股转换为7,675,160普通股，此转换包括应计未支付股息的附加股份。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间